ALIVUS Life Sciences provided an update on the fire incident that occurred on February 14, 2026, at its Dahej manufacturing facility. The fire was confined to one block, specifically affecting intermediate manufacturing facilities. Crucially, Active Pharmaceutical Ingredient (API) units in that block were unaffected. The company anticipates resuming API production by March 1, 2026, with intermediate production restarting mid-March, expecting minor shipment delays.
Update on Dahej Manufacturing Facility Incident
ALIVUS Life Sciences Limited has released further information regarding the fire incident that took place on February 14, 2026, at one of the seven production blocks within its Dahej manufacturing facility in Gujarat. Following the initial intimation provided on February 16, the company confirmed that the situation is now fully assessed.
Impact Assessment and Operational Status
The incident was successfully contained to a single production block. While this block sustained damage affecting a portion of its intermediate manufacturing capabilities, the Active Pharmaceutical Ingredient (API) manufacturing facilities within the same block remained entirely unaffected. Furthermore, all six other production blocks at the Dahej site are reported to be fully operational and unaffected by the event.
Resumption Timeline and Outlook
The company has finalized its assessment and set clear recovery timelines. ALIVUS Life Sciences expects to resume API production at the affected block starting March 1, 2026. Production of intermediates is scheduled to recommence in the middle of March 2026. The management noted that this temporary cessation of specific operations will regrettably lead to a few delayed shipments.
Commitment to Safety
ALIVUS emphasized that safety remains paramount. The organization adheres to stringent safety standards and protocols across all operations and is continuing to implement all necessary precautionary measures to prevent any recurrence of such incidents.
Source: BSE
